InvestorsHub Logo

Blue Fin

08/03/21 9:00 AM

#368538 RE: DaubersUP #368535

I wasn't aware that "B" wasn't being used alone and thought the SOC was the Placebo?

MackG

08/03/21 9:01 AM

#368539 RE: DaubersUP #368535

Applying a bit of logic, take a look at HOW MUCH MORE EFFECTIVE the combo treatment was as compared to the soc alone. The difference in the IMPROVEMENT can only be attributable to Brilacidan.

frenchbroad

08/03/21 9:07 AM

#368542 RE: DaubersUP #368535

*How do we know it wasn’t because of COMBO with SOC? We will not know if B can be used alone at this point…correct?*

No, we will not know if Brilacidin can be used alone at this point.

But the addition of Brilacidin to the standard of care will become the new standard of care, if Brialcidin helps. That is good enough for me.

ROMAD Diver

08/03/21 9:10 AM

#368543 RE: DaubersUP #368535

This is an excellent question. I am hoping for not only reduced time of infection, but also reduced times for those who had pneumonia and other complications prior to receiving Brilacidin in order to show the true value of the drug.

If we were to get 90% of patients COVID-free by day 15, and say, 100% of 30 patients who had pneumonia pre-injection became pneumonia-free by day 15 as well, then the data becomes stronger.

farrell90

08/03/21 9:22 AM

#368547 RE: DaubersUP #368535

There is a control SOC group with 60 pts and a treatment group of 60 pts with the SOC +Brilacidin.

THE FDA and others felt the study without SOC treatment for both groups was unethical. The Phase 3 study may have direct comparisons.

ACTI-6, a large trial with multiple repurposed drugs, has begun. It is possible Brilacidin will be a part of a future similar study if the phase 2 study is possible.

https://www.nih.gov/news-events/news-releases/large-clinical-trial-study-repurposed-drugs-treat-covid-19-symptoms.



GLTA Farrell